Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Bolt Biotherapeutics Inc (BOLT)

Bolt Biotherapeutics Inc (BOLT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update GlobeNewswire - Tue Nov 12, 3:05PM CST

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting GlobeNewswire - Thu Nov 7, 9:00AM CST

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Globe Newswire - Wed Aug 10, 2022

– BDC-1001 monotherapy and combination dose-escalation portion of the trial in HER2-expressing solid tumors on track to complete this year– New portfolio...

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022 Globe Newswire - Fri May 27, 2022

- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present - REDWOOD CITY, Calif., May 27, 2022 (GLOBE...

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights Globe Newswire - Thu May 12, 2022

–   BDC-1001 monotherapy and OPDIVO® combination trials progressing toward data readouts in second half of 2022 –   Cash balance of $246.8 million...

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference Globe Newswire - Thu Apr 7, 2022

REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new...

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights Globe Newswire - Wed Mar 30, 2022

BDC-1001 for the treatment of patients with HER2-expressing solid tumors on track for recommended Phase 2 dose identification later in 2022; BDC-1001...

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022 Globe Newswire - Tue Mar 8, 2022

REDWOOD CITY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new...

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021 Globe Newswire - Mon Dec 6, 2021

Company to continue monotherapy dose-escalation and evaluate weekly dose regimen Combination dose-escalation study of BDC-1001 with Opdivo® on target to...

BOLT : 0.6260 (-0.62%)
Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021 Globe Newswire - Thu Dec 2, 2021

REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a...

BOLT : 0.6260 (-0.62%)

Barchart Exclusives

Buy the Dip in This Dividend Aristocrat for a Strong 2025 Barchart - 17 minutes ago
McDonald's has faced challenges in 2024, including an E. coli outbreak, but is investing $100 million to recover and win back customers. With a strong brand, solid finances, and a clear growth strategy, the company's recent dip presents a rare chance to invest in a proven market leader with a long-term dividend growth streak. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot